1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21935
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWasik, A. M.en
dc.contributor.authorGandy, M. N.en
dc.contributor.authorMcIldowie, M.en
dc.contributor.authorHolder, M. J.en
dc.contributor.authorChamba, A.en
dc.contributor.authorChalla, A.en
dc.contributor.authorLewis, K. D.en
dc.contributor.authorYoung, S. P.en
dc.contributor.authorScheel-Toellner, D.en
dc.contributor.authorDyer, M. J.en
dc.contributor.authorBarnes, N. M.en
dc.contributor.authorPiggott, M. J.en
dc.contributor.authorGordon, J.en
dc.date.accessioned2015-11-24T19:19:09Z-
dc.date.available2015-11-24T19:19:09Z-
dc.identifier.issn1573-0646-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21935-
dc.rightsDefault Licence-
dc.titleEnhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell deathen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s10637-011-9730-5-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21850491-
heal.identifier.secondaryhttp://www.springerlink.com/content/384k8r14u2kvhv1h/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractWhile 3,4-methylenedioxymethamphetamine (MDMA/'ecstasy') is cytostatic towards lymphoma cells in vitro, the concentrations required militate against its translation directly to a therapeutic in vivo. The possibility of 'redesigning the designer drug', separating desired anti-lymphoma activity from unwanted psychoactivity and neurotoxicity, was therefore mooted. From an initial analysis of MDMA analogues synthesized with a modified alpha-substituent, it was found that incorporating a phenyl group increased potency against sensitive, Bcl-2-deplete, Burkitt's lymphoma (BL) cells 10-fold relative to MDMA. From this lead, related analogs were synthesized with the 'best' compounds (containing 1- and 2-naphthyl and para-biphenyl substituents) some 100-fold more potent than MDMA versus the BL target. When assessed against derived lines from a diversity of B-cell tumors MDMA analogues were seen to impact the broad spectrum of malignancy. Expressing a BCL2 transgene in BL cells afforded only scant protection against the analogues and across the malignancies no significant correlation between constitutive Bcl-2 levels and sensitivity to compounds was observed. Bcl-2-deplete cells displayed hallmarks of apoptotic death in response to the analogues while BCL2 overexpressing equivalents died in a caspase-3-independent manner. Despite lymphoma cells expressing monoamine transporters, their pharmacological blockade failed to reverse the anti-lymphoma actions of the analogues studied. Neither did reactive oxygen species account for ensuing cell death. Enhanced cytotoxic performance did however track with predicted lipophilicity amongst the designed compounds. In conclusion, MDMA analogues have been discovered with enhanced cytotoxic efficacy against lymphoma subtypes amongst which high-level Bcl-2-often a barrier to drug performance for this indication-fails to protect.en
heal.journalNameInvest New Drugsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Wasik-2011-Enhancing the anti-l.pdf675.41 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons